<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01902082</url>
  </required_header>
  <id_info>
    <org_study_id>MSCs in ARDS</org_study_id>
    <nct_id>NCT01902082</nct_id>
  </id_info>
  <brief_title>Adipose-derived Mesenchymal Stem Cells in Acute Respiratory Distress Syndrome</brief_title>
  <official_title>Phase I Study of Allogeneic Adipose-derived Mesenchymal Stem Cells in Acute Respiratory Distress Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shaoxing Second Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shaoxing Second Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Currently, there is no proven effective pharmacologic treatment available for patients with
      the acute respiratory distress syndrome (ARDS). Mesenchymal stem cells have been shown to be
      effective in treating several inflammatory diseases. The main purpose of this study is to
      assess the safety of allogeneic adipose-derived mesenchymal stem cells in patients with ARDS.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>November 2012</start_date>
  <completion_date type="Anticipated">June 2014</completion_date>
  <primary_completion_date type="Anticipated">June 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Compare the adverse events between mesenchymal stem cell treatment and placebo groups</measure>
    <time_frame>From day 0 at the start of treatment to day 28.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hospital indices by treatment group</measure>
    <time_frame>From admission to discharge</time_frame>
    <description>Days in hospital ICU free days at day 28 Ventilator free days at day 28</description>
  </secondary_outcome>
  <other_outcome>
    <measure>cytokines</measure>
    <time_frame>Day 0 to day 7</time_frame>
    <description>IL-6, IL-8, SP-D, TNF-alpha</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>ARDS</condition>
  <arm_group>
    <arm_group_label>Mesenchymal stem cell arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients received one dose of 1x 10^6 allogeneic adipose-derived mesenchymal stem cells/kg body weight intravenously within 48 hours of enrollment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients received one dose of normal saline.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mesenchymal stem cells</intervention_name>
    <arm_group_label>Mesenchymal stem cell arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Intravenous saline infusion will be designated as placebo.</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. ARDS diagnosed using Berlin definition

          2. Eligible patients were at least 18 years of age had acute onset of ARDS.

          3. Bilateral opacities in chest radiography

          4. No cardiac failure

          5. PaO2/FiO2 ratio &lt; 200

        Exclusion Criteria:

          1. 72 hours after all inclusion criteria met

          2. Pre-existing severe diseases of any major organs

          3. Pregnancy

          4. Pulmonary hypertension

          5. Malignant diseases

          6. HIV infections.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Guoping Zheng, MD</last_name>
    <phone>13385851678</phone>
    <email>zgp28037@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jianguo Xu, PhD</last_name>
    <phone>575-88053995</phone>
    <email>jxu6325@yahoo.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Shaoxing Second Hospital</name>
      <address>
        <city>Shaoxing</city>
        <state>Zhejiang</state>
        <zip>312000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guoping Zheng, MD</last_name>
      <phone>13385851678</phone>
      <email>zgp28037@163.com</email>
    </contact>
    <contact_backup>
      <last_name>Jianguo Xu, PhD</last_name>
      <phone>575-88053995</phone>
      <email>jxu6325@yahoo.com</email>
    </contact_backup>
    <investigator>
      <last_name>Jianguo Xu, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Guoping Zheng, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 14, 2013</study_first_submitted>
  <study_first_submitted_qc>July 14, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 18, 2013</study_first_posted>
  <last_update_submitted>July 14, 2013</last_update_submitted>
  <last_update_submitted_qc>July 14, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 18, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ARDS</keyword>
  <keyword>mesenchymal stem cells</keyword>
  <keyword>Safety</keyword>
  <keyword>Cytokines</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Distress Syndrome, Newborn</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Adult</mesh_term>
    <mesh_term>Acute Lung Injury</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

